5 November 2024NewsAmericasOlga Zimmerman Director Intellectual Property Caribou Biosciences, Matthew Gordon Vice President Legal Myriad Genetics Inc, Susan Krumplitsch Partner DLA Piper, William Mulholland Partner DLA Piper, Graham Cole Director Intellectual Property Office of Technology Licensing City of Hope
WATCH: Navigating enablement and written description requirement standards in the USPTO
On January 10 this year, the director of the USPTO issued new guidelines on enablement under 35 U.S.C §112. In recent years, the landscape of patent law in the United States has undergone a significant shift, with courts adopting a more stringent stance on the criteria of enablement and written description.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com
10 July 2026 Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.
9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
2 July 2026 A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.